FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
bioMérieux, a world leader in the field of in vitro diagnostics, today announced the acquisition of Applied Maths, a company that develops state-of-the-art software solutions for the biosciences, in particular for databasing, analysis and interpretation of complex biological data. Since it was founded in 1992, the company has gained worldwide recognition by leveraging its strong and unique combined expertise in informatics and microbiology. read more
MDxHealth SA (Euronext Brussels: MDXH) (the "Company") announced today that it succesfully completed the acquisition of all of the shares in NovioGendix Holding B.V. ("NovioGendix"). The acquisition of NovioGendix was announced on September 15, 2015 and the completion of the acquisition took place on September 18, 2015. read more
MDxHealth SA (Euronext: MDXH.BR), today announced that it has entered into an agreement to acquire NovioGendix, a privately-held molecular diagnostics company focused on the development of a non-invasive liquid biopsy test for prostate cancer. read more
ViroVet BVBA, a privately owned company focused on the discovery, licensing, and development of innovative biopharmaceutical products for livestock, today announced that it has commenced operations. ViroVet is a spin-out of Aratana Therapeutics NV (formerly Okapi Sciences NV). read more
Mentha Capital, an independent investment firm focused on smaller midsize companies in the Benelux, has acquired a majority stake in Pharmavize. read more
Spinifex Pharmaceuticals, Inc. (“Spinifex”), a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG (“Novartis”), for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments. read more
Toonaangevend ontwikkelaar en leverancier van industriële test- en meetoplossingen Test & Measurement Solutions (T&M Solutions) noteerde in 2014 een groei van 15%, ondanks de crisis. Om haar internationale expansie verder te zetten en extra arbeidsplaatsen te creëren, investeert het Limburgse bedrijf in nieuwe vestigingen in Nederland en Polen. Daarnaast zet het bedrijf volop in op blijvende bijscholing van haar medewerkers om hoogtechnologische expertise te garanderen bij het verstrekken van kwaliteitsgaranties voor producten en bij het optimaliseren van productieprocessen. read more
BONE THERAPEUTICS, the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces the official opening of its new headquarters at the Gosselies Biopark in Belgium. Bone Therapeutics’ new facility is being officially opened in the presence of Mr Paul Magnette, Minister-President of Wallonia, and Mr Jean-Claude Marcourt, Vice-President of the Walloon Government. read more
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces the foundation of Oncurious NV, a new oncology company that will develop TB-403 for the treatment of pediatric brain tumors. VIB, a leading life sciences institute in Flanders (Belgium), will become a shareholder alongside ThromboGenics in this new oncology venture. ThromboGenics will be the majority shareholder. read more
BONE THERAPEUTICS, the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces that it has established its US based subsidiary, Bone Therapeutics USA Inc. in Boston, Massachusetts, in line with its strategy as outlined at the time of its recent initial public offering. The establishment of the US headquarters is the first step for the Company to move forward its US clinical trials programme. read more